Bingshu E. Chen
机构: Professor of Biostatistics, Queens University, Canada
每年引用次数
引用次数
引用: 10,540
H-指数: 47
I10-指数 : 97
出版物: 208
Incremental net benefit in randomized clinical trials with quality-adjusted survival.
Andrew R. Willan , Eric Bingshu Chen , Richard J. Cook , D. Y. Lin
Statistics in Medicine 22 ( 3) 353 -362
39
2003
Regression modeling with recurrent events and time-dependent interval-censored marker data.
Eric Bingshu Chen , Richard J. Cook
Lifetime Data Analysis 9 ( 3) 275 -291
9
2003
Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
Sholom Wacholder , Bingshu Eric Chen , Allen Wilcox , George Macones
BMJ 340 ( 7748)
82
2010
Differential effects of smoking on lung cancer mortality before and after household stove improvement in Xuanwei, China.
K-M Lee , R S Chapman , M Shen , J H Lubin
British Journal of Cancer 103 ( 5) 727 -729
20
2010
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial
J M S Bartlett , , T O Nielsen , D Gao
British Journal of Cancer 113 ( 5) 722 -728
4
2015
Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study
M Walker , A Szeto , Z Meng , B E Chen
Canadian Cancer Research Conference, Toronto, ON
2011
A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia
Nicole Mittmann , Jennifer A. Woyach , Sumithra J Mandrekar , Michael Crump
Blood 136 27 -30
2020
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
Kim Leitzel , Suhail M Ali , Lois E Shepherd , Wendy R Parulekar
Journal of Clinical Oncology 36 1031 -1031
3
2018
Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy - Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial
Mina Dehghani Mohammadabadi , Annette E Hay , Lois E. Shepherd , Michael Crump
Blood 132 2980 -2980
2018
MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies
Christopher P. Venner , Richard Leblanc , Irwindeep Sandhu , Darrell J. White
Blood 132 1984 -1984
1
2018
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Prashanth Moku , Lois Shepherd , Suhail M. Ali , Kim Leitzel
Cancer 126 ( 22) 4859 -4866
1
2020
Trends and demographic characteristics of physical fighting and fighting-related injuries among Canadian youth, 1993-2010.
Maya Djerboua , Bingshu E. Chen , Colleen Davison
Canadian Journal of Public Health-revue Canadienne De Sante Publique 107 ( 3) 231 -238
4
2016
Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis
Ismail Jatoi , Bingshu E. Chen , William F. Anderson , Philip S. Rosenberg
Journal of Clinical Oncology 25 ( 13) 1683 -1690
182
2007
Competing Risks Analysis of Correlated Failure Time Data
Bingshu E. Chen , Joan L. Kramer , Mark H. Greene , Philip S. Rosenberg
Biometrics 64 ( 1) 172 -179
34
2008
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.
Ming Han , Alli Murugesan , Nizar J. Bahlis , Kevin Song
Blood 128 ( 5) 732 -735
1
2016
Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers
Joan L. Kramer , Isela A. Velazquez , Bingshu E. Chen , Philip S. Rosenberg
Journal of Clinical Oncology 23 ( 34) 8629 -8635
126
2005
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL.
Sarit Assouline , Shen Li , Christian Gisselbrecht , Patrick Fogarty
Blood Advances 4 ( 9) 2011 -2017
2
2020
Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions
William F. Anderson , Rayna K. Matsuno , Mark E. Sherman , Jolanta Lissowska
Cancer Causes & Control 18 ( 4) 439 -447
50
2007
Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers
William F. Anderson , Bingshu E. Chen , Louise A. Brinton , Susan S. Devesa
Cancer Causes & Control 18 ( 10) 1187 -1198
40
2007
Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone
Bernd Dörken , Robert G. Pearcey , Volker Diehl , Sandra J. Horning
Blood 120 ( 21) 548 -548
6
2012